Publications:

Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia.

Signal Transduction And Targeted Therapy

Zhang, Qi Q; Riley-Gillis, Bridget B; Han, Lina L; Jia, Yannan Y; Lodi, Alessia A; Zhang, Haijiao H; Ganesan, Saravanan S; Pan, Rongqing R; Konoplev, Sergej N SN; Sweeney, Shannon R SR; Ryan, Jeremy A JA; Jitkova, Yulia Y; Dunner, Kenneth K; Grosskurth, Shaun E SE; Vijay, Priyanka P; Ghosh, Sujana S; Lu, Charles C; Ma, Wencai W; Kurtz, Stephen S; Ruvolo, Vivian R VR; Ma, Helen H; Weng, Connie C CC; Ramage, Cassandra L CL; Baran, Natalia N; Shi, Ce C; Cai, Tianyu T; Davis, Richard Eric RE; Battula, Venkata L VL; Mi, Yingchang Y; Wang, Jing J; DiNardo, Courtney D CD; Andreeff, Michael M; Tyner, Jeffery W JW; Schimmer, Aaron A; Letai, Anthony A; Padua, Rose Ann RA; Bueso-Ramos, Carlos E CE; Tiziani, Stefano S; Leverson, Joel J; Popovic, Relja R; Konopleva, Marina M

Publication Date: 2022-02-21

Variant appearance in text: PC: 1097A>G; Asn366Ser

PubMed Link: 35185150

Variant Present in the following documents:

• 41392_2021_870_MOESM1_ESM.pdf

View BVdb publication page